Pharma BD Deal Intelligence
The transaction exemplifies two trends: diversified players such as Abbott rotating toward devices/diagnostics, and generics consolidators using inversion to…
JPMorgan's Michael Weinstein called the transaction 'a win for both companies' — Abbott monetizes an eroding European drug business while Mylan gets a lower…
Mylan and Abbott would proceed with their tax-inversion deal despite tightened Treasury rules, with Mylan reincorporating in the Netherlands as 'New Mylan' to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Mylan agreed to acquire Abbott's non-U.S. developed-markets specialty and branded generics business in an all-stock deal valued at approximately $5.3B, structured as a tax inversion that domiciled the combined Mylan in the Netherlands. Closed February 27, 2015 and added ~$1.9B in annualized revenue.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) (this deal) | 2014 | $5.3B | 33 |
| Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) | 2015 | $265M | 61 |
| Mylan Inc. / Bioniche Pharma Holdings Limited | 2010 | $550M | 60 |
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) | 2015 | $800M | 56 |
| Mylan Inc. / Agila Specialties (Strides Arcolab) | 2013 | $1.8B | 45 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
← Browse all deals · How we score deals
More: 2014 deals · Mylan Inc. deals · Other deals